Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsWAR:RVU -2.09%66 Days Payable is 340.67 as of Mar. 2026, which is 4% below its 10-year median of 355.22. GuruFocus rates WAR:RVU with a GF Score™ of 66/100 and a GF Value™ of zł45.84 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Ryvu Therapeutics ranks better than 78.6% on this metric.
The historical rank and industry rank for Ryvu Therapeutics's Days Payable or its related term are showing as below:
WAR:RVU'
s Days Payable Range Over the Past 10 Years
Min: 61.32 Med: 355.22 Max: 584.19
Current: 471.64
During the past 13 years, Ryvu Therapeutics's highest Days Payable was 584.19. The lowest was 61.32. And the median was 355.22.
WAR:RVU's Days Payable is ranked better than 78.6% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs WAR:RVU: 471.64
Ryvu Therapeutics's Days Payable
declined
from Mar. 2025 (675.50) to Mar. 2026 (340.67).
It may suggest that Ryvu Therapeuticsaccelerated paying its suppliers.
Ryvu Therapeutics Days Payable Related Terms
Ryvu Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RVU vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ryvu Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (WAR:RVU) has a Days Payable of 340.67 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ryvu Therapeutics and its competitors. This is near median its historical median of 355.22. Over the past decade, Ryvu Therapeutics' Days Payable has ranged from 61.32 to 584.19. According to the industry distribution chart, Ryvu Therapeutics ranks #150 out of 701 companies in the Biotechnology industry, placing it in the top 21.4%.
Is Ryvu Therapeutics' Days Payable too high?
Ryvu Therapeutics' current Days Payable of 340.67 is near median its 10-year median of 355.22. Over the past 10 years, this metric has ranged from a low of 61.32 to a high of 584.19. The Biotechnology industry median Days Payable is 112.84. Ryvu Therapeutics' value of 340.67 is 201.9% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #150 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #150 out of 701 companies for Days Payable. This places Ryvu Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Ryvu Therapeutics' value of 340.67 is 201.9% above this benchmark. Historically, Ryvu Therapeutics' own Days Payable has ranged from 61.32 to 584.19 over the past decade. While the company's 10-year median is 355.22 vs. the industry median of 112.84, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Days Payable of 340.67 is 201.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Days Payable is 340.67, which is near median its own 10-year median of 355.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł14.98 — trading 67.3% below its estimated fair value. The current Days Payable is 340.67, which is near median its 10-year median of 355.22 and 201.9% above the Biotechnology industry median of 112.84. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Days Payable is 340.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for WAR:RVU:
Days Payable: 340.67 (near median its 10-year median of 355.22)
GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
Industry Position: 201.9% above the Biotechnology median (#150 of 701)
No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for WAR:RVU
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RVU has been successfully added to your 
